PL4313293T3 - Pochodne tetrahydrotienopirydyny jako inhibitory DDR - Google Patents

Pochodne tetrahydrotienopirydyny jako inhibitory DDR

Info

Publication number: PL4313293T3
Authority: PL; Poland
Prior art keywords: ddrs; inhibitors; pyridine derivatives; tetrahydrothieno; tetrahydrothieno pyridine
Prior art date: 2021-03-26

Application number

PL22719225.9T

Other languages

English (en)

Inventor

Laura Carzaniga

Andrea Rizzi

Nicolò IOTTI

Fabio Rancati

Anna KARAWAJCZYK

Barbara Karolina Wolek

David Edward Clark

Toby Matthew Grover MULLINS

Keith Christopher KNIGHT

Ben Paul WHITTAKER

Stefano LEVANTO

Original Assignee

Chiesi Farmaceutici S.P.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2021-03-26

Filing date

2022-03-25

Publication date

2025-09-01

2022-03-25 Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.

2025-09-01 Publication of PL4313293T3 publication Critical patent/PL4313293T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Otolaryngology (AREA)
Ophthalmology & Optometry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)
Diabetes (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

PL22719225.9T 2021-03-26 2022-03-25 Pochodne tetrahydrotienopirydyny jako inhibitory DDR PL4313293T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP21165288		2021-03-26
EP21209682		2021-11-22
PCT/EP2022/057942 WO2022200580A1 (en)	2021-03-26	2022-03-25	Tetrahydrothieno pyridine derivatives as ddrs inhibitors

Publications (1)

Publication Number	Publication Date
PL4313293T3 true PL4313293T3 (pl)	2025-09-01

Family

ID=81389152

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL22719225.9T PL4313293T3 (pl)	2021-03-26	2022-03-25	Pochodne tetrahydrotienopirydyny jako inhibitory DDR

Country Status (29)

Country	Link
US (1)	US20240391936A1 (pl)
EP (2)	EP4506349A3 (pl)
JP (1)	JP2024512595A (pl)
KR (1)	KR20230163464A (pl)
CN (1)	CN120574244A (pl)
AU (1)	AU2022244189A1 (pl)
BR (1)	BR112023019437A2 (pl)
CA (1)	CA3212775A1 (pl)
CL (2)	CL2023002821A1 (pl)
CO (1)	CO2023014012A2 (pl)
DK (1)	DK4313293T3 (pl)
ES (1)	ES3036380T3 (pl)
FI (1)	FI4313293T3 (pl)
GE (2)	GEAP202416606A (pl)
HR (1)	HRP20250808T1 (pl)
HU (1)	HUE072171T2 (pl)
IL (1)	IL306062A (pl)
LT (1)	LT4313293T (pl)
MA (1)	MA63982B1 (pl)
MD (1)	MD4313293T2 (pl)
MX (1)	MX2023011060A (pl)
PE (1)	PE20240358A1 (pl)
PL (1)	PL4313293T3 (pl)
RS (1)	RS67088B1 (pl)
SI (1)	SI4313293T1 (pl)
SM (1)	SMT202500288T1 (pl)
TW (1)	TW202304938A (pl)
WO (1)	WO2022200580A1 (pl)
ZA (2)	ZA202309968B (pl)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2003073357A (ja) *	2001-09-03	2003-03-12	Mitsubishi Pharma Corp	アミド化合物を含有するＲｈｏキナーゼ阻害剤
AU2015335980A1 (en)	2014-10-22	2017-05-18	Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences	Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof
CN104490889B (zh) *	2014-12-30	2016-04-20	中国人民解放军第四军医大学	一种 ddr2 小分子抑制剂抗肺纤维化应用
JP7002335B2 (ja) *	2015-07-03	2022-01-20	エフ．ホフマン－ラロシュアーゲー	Ｄｄｒ１阻害剤としてのトリアザ－スピロデカノン
UA123219C2 (uk) *	2015-10-23	2021-03-03	Віфор (Інтернаціональ) Аґ	Інгібітори феропортину
CN108191885B (zh) *	2018-01-29	2020-08-04	华东师范大学	一类哌啶并噻吩类小分子有机化合物及其应用
CN108558848A (zh) *	2018-04-19	2018-09-21	华东师范大学	一种环烷烃并噻吩衍生物及其制备方法和医药用途
CN111138449B (zh) *	2020-01-15	2022-11-29	四川大学华西医院	双靶向erk1和erk5抑制剂的制备及其抗肿瘤应用

2022
- 2022-03-25 MD MDE20240152T patent/MD4313293T2/ro unknown
- 2022-03-25 BR BR112023019437A patent/BR112023019437A2/pt active Search and Examination
- 2022-03-25 IL IL306062A patent/IL306062A/en unknown
- 2022-03-25 KR KR1020237036602A patent/KR20230163464A/ko active Pending
- 2022-03-25 EP EP24221423.7A patent/EP4506349A3/en active Pending
- 2022-03-25 MA MA63982A patent/MA63982B1/fr unknown
- 2022-03-25 HU HUE22719225A patent/HUE072171T2/hu unknown
- 2022-03-25 ES ES22719225T patent/ES3036380T3/es active Active
- 2022-03-25 SI SI202230139T patent/SI4313293T1/sl unknown
- 2022-03-25 US US18/283,861 patent/US20240391936A1/en active Pending
- 2022-03-25 PE PE2023002683A patent/PE20240358A1/es unknown
- 2022-03-25 DK DK22719225.9T patent/DK4313293T3/da active
- 2022-03-25 TW TW111111315A patent/TW202304938A/zh unknown
- 2022-03-25 CA CA3212775A patent/CA3212775A1/en active Pending
- 2022-03-25 WO PCT/EP2022/057942 patent/WO2022200580A1/en not_active Ceased
- 2022-03-25 EP EP22719225.9A patent/EP4313293B1/en active Active
- 2022-03-25 GE GEAP202416606A patent/GEAP202416606A/en unknown
- 2022-03-25 MX MX2023011060A patent/MX2023011060A/es unknown
- 2022-03-25 SM SM20250288T patent/SMT202500288T1/it unknown
- 2022-03-25 AU AU2022244189A patent/AU2022244189A1/en active Pending
- 2022-03-25 RS RS20250730A patent/RS67088B1/sr unknown
- 2022-03-25 FI FIEP22719225.9T patent/FI4313293T3/fi active
- 2022-03-25 HR HRP20250808TT patent/HRP20250808T1/hr unknown
- 2022-03-25 LT LTEPPCT/EP2022/057942T patent/LT4313293T/lt unknown
- 2022-03-25 GE GEAP202416376A patent/GEP20267870B/en unknown
- 2022-03-25 JP JP2023558776A patent/JP2024512595A/ja active Pending
- 2022-03-25 CN CN202510886806.3A patent/CN120574244A/zh active Pending
- 2022-03-25 PL PL22719225.9T patent/PL4313293T3/pl unknown
2023
- 2023-09-22 CL CL2023002821A patent/CL2023002821A1/es unknown
- 2023-10-20 CO CONC2023/0014012A patent/CO2023014012A2/es unknown
- 2023-10-25 ZA ZA2023/09968A patent/ZA202309968B/en unknown
2024
- 2024-08-30 CL CL2024002602A patent/CL2024002602A1/es unknown
- 2024-10-22 ZA ZA2024/07966A patent/ZA202407966B/en unknown

Also Published As

Publication number	Publication date
CL2023002821A1 (es)	2024-03-22
HUE072171T2 (hu)	2025-10-28
LT4313293T (lt)	2025-06-25
EP4313293A1 (en)	2024-02-07
AU2022244189A1 (en)	2023-11-09
MD4313293T2 (ro)	2025-08-31
GEP20267870B (en)	2026-03-10
CN120574244A (zh)	2025-09-02
ZA202309968B (en)	2025-03-26
ZA202407966B (en)	2026-01-28
WO2022200580A1 (en)	2022-09-29
JP2024512595A (ja)	2024-03-19
GEAP202416376A (en)	2024-01-25
HRP20250808T1 (hr)	2025-09-12
GEAP202416606A (en)	2024-11-25
MX2023011060A (es)	2023-09-29
CL2024002602A1 (es)	2025-02-07
BR112023019437A2 (pt)	2023-10-24
DK4313293T3 (da)	2025-06-10
MA63982B1 (fr)	2025-05-30
SMT202500288T1 (it)	2025-09-12
TW202304938A (zh)	2023-02-01
CA3212775A1 (en)	2022-09-29
PE20240358A1 (es)	2024-02-27
ES3036380T3 (en)	2025-09-18
EP4313293B1 (en)	2025-05-07
SI4313293T1 (sl)	2025-07-31
EP4506349A3 (en)	2025-05-07
CO2023014012A2 (es)	2024-03-07
EP4506349A2 (en)	2025-02-12
RS67088B1 (sr)	2025-09-30
IL306062A (en)	2023-11-01
US20240391936A1 (en)	2024-11-28
KR20230163464A (ko)	2023-11-30
FI4313293T3 (fi)	2025-08-07

Publication	Publication Date	Title
IL310403A (en)	2024-03-01	Converted pyridine derivatives as SARM1 inhibitors
ZA201904737B (en)	2020-05-27	Pyridine derivative as ask1 inhibitor and preparation method and use thereof
IL263404B (en)	2019-09-26	History of ring-fused bicyclic pyridyls as fgfr4 inhibitors
SG11202011165TA (en)	2020-12-30	Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
ZA201705802B (en)	2019-07-31	4h-pyrrolo[3,2-c]pyridin-4-one derivatives
ZA201808257B (en)	2020-05-27	1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
CA3256849A1 (en)	2025-10-31	Synchronization signal transmission for mobility
SI2951172T1 (sl)	2017-08-31	Piridin derivati kot inhibitorji mehkih kamnov
IL258341A (en)	2018-05-31	New imidazo[4,5-b]pyridine derivatives as dual dyrk1/clk1 inhibitors
IL269214B (en)	2022-03-01	Novel imidazo[5,4-c]quinoline derivatives as lrrk2 inhibitors
EP3858834A4 (en)	2022-06-22	PYRAZOLOPYRIMIDE DERIVATIVES AS SELECTIVE TRK INHIBITORS
PL4396183T3 (pl)	2026-02-09	Podstawione pochodne s-alaninianu
IL288950A (en)	2022-02-01	History of pyridine-3-yl
PT4313293T (pt)	2025-07-25	Derivados de tetraidrotieno piridina como inibidores de ddrs
PL4313293T3 (pl)	2025-09-01	Pochodne tetrahydrotienopirydyny jako inhibitory DDR
PL4313994T3 (pl)	2025-06-23	Pochodne tetrahydrotienopirydyny jako inhibitory DDR
IL281811A (en)	2021-05-31	Thiano[3,2-B]pyridine derivatives as UPD glycosyltransferase inhibitors and methods of use
EP3302060A4 (en)	2018-12-05	Pyrazolo[4,3-c]quinoline derivatives for inhibition of -glucuronidase
HK40110746A (en)	2024-12-20	Substituted pyridine derivatives as sarm1 inhibitors
HK40068930A (en)	2022-09-30	Substituted 5-cyclopropyl-1h-pyrazol-3-yl-amine derivatives as selective cdk12/13 inhibitors
CA3294653A1 (en)	2024-12-12	Heteroaryl derivatives as ddrs inhibitors
HK40060820B (zh)	2026-04-10	作为p2x3抑制剂的吡啶并嘧啶类衍生物
HK40041290A (en)	2021-08-13	Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors
HK40113674A (en)	2025-02-21	Sestrin-mapk complex inhibitors
HK40080738A (en)	2023-05-05	Tricyclic heterocycles as fgfr inhibitors